Behandlung eines therapieresistenten Pemphigus vulgaris mit Rituximab und Immunglobulinen-Reference-Cited by-同舟云学术

Behandlung eines therapieresistenten Pemphigus vulgaris mit Rituximab und Immunglobulinen

Published:2007-10-21 Issue:11 Volume:58 Page:924-926
ISSN:0017-8470
Container-title:Der Hautarzt
language:de
Short-container-title:Hautarzt

Author:

Mühlhoff C.,Megahed M.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s00105-007-1414-x.pdf

Reference11 articles.

1. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (2006) Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355: 1772–1779

2. Bermudez A, Marco F, Conde E et al. (2000) Fatal varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85: 894–895

3. Bystryn JC, Steinmann NM (1996) The adjuvant therapy of pemphigus: an update. Arch Dermatol 132: 203-212

4. Dupuy A, Viguier M, Bedane C et al. (2004) Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 140: 91–96

5. El Tal Ak, Posner MR, Spigelman Z, Ahmed AR (2006) Rituximab: a monoklonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 55: 449–459

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab in Severe Pemphigus;Annals of the New York Academy of Sciences;2009-09

2. Interventions for pemphigus vulgaris and pemphigus foliaceus;Cochrane Database of Systematic Reviews;2009-01-21

3. CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab;Expert Review of Dermatology;2008-06